MA
DNA icon

MYDA Advisors’s Ginkgo Bioworks DNA Stock Holding History

MYDA Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,500
Closed -$167K – 159
2024
Q2 		$167K Buy
+12,500
New +$373K 0.04% 114
2022
Q4 		– Sell
-6,000
Closed -$749K – 92
2022
Q3 		$749K Buy
6,000
+750
+14% +$89.4K 0.35% 79
2022
Q2 		$500K Buy
5,250
+1,300
+33% +$159K 0.14% 117
2022
Q1 		$637K Buy
+3,950
New +$769K 0.25% 106
2021
Q4 		– Sell
-1,657
Closed -$768K – 275
2021
Q3 		$768K Buy
+1,657
New +$807K 0.21% 120

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MYDA Advisors's DNA Position: Q3 2024 in Review

MYDA Advisors sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 12,500 shares — an estimated $167K sold.

MYDA Advisors first reported a position in DNA in Q3 2021 and held it in 5 quarters. The position peaked at $768K in Q3 2021. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • MYDA Advisors reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • MYDA Advisors sold 12,500 Ginkgo Bioworks shares in Q3 2024, an estimated $167K.
  • MYDA Advisors first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 5 quarters.
  • MYDA Advisors's Ginkgo Bioworks position peaked at $768K in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on MYDA Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.